Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season
Clinical Infectious Diseases · 17.04.2023 · 76 (8) · 1358-1363
DOI: 10.1093/cid/ciac941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 12.12.2022. Verfasst von Ashley M Price und 19 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, COVID-19. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, CDC, NIH.
Abstract (Originalsprache)
Background
In the United States, influenza activity during the 2021–2022 season was modest and sufficient enough to estimate influenza vaccine effectiveness (VE) for the first time since the beginning of the coronavirus disease 2019 pandemic. We estimated influenza VE against laboratory-confirmed outpatient acute illness caused by predominant A(H3N2) viruses.
Methods
Between October 2021 and April 2022, research staff across 7 sites enrolled patients aged ≥6 months seeking outpatient care for acute respiratory illness with cough. Using a test-negative design, we assessed VE against influenza A(H3N2). Due to strong correlation between influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, participants who tested positive for SARS-CoV-2 were excluded from VE estimations. Estimates were adjusted for site, age, month of illness, race/ethnicity, and general health status.
Results
Among 6260 participants, 468 (7%) tested positive for influenza only, including 440 (94%) for A(H3N2). All 206 sequenced A(H3N2) viruses were characterized as belonging to genetic group 3C.2a1b subclade 2a.2, which has antigenic differences from the 2021–2022 season A(H3N2) vaccine component that belongs to clade 3C.2a1b subclade 2a.1. After excluding 1948 SARS-CoV-2–positive patients, 4312 patients were included in analyses of influenza VE; 2463 (57%) were vaccinated against influenza. Effectiveness against A(H3N2) for all ages was 36% (95% confidence interval, 20%–49%) overall.
Conclusions
Influenza vaccination in 2021–2022 provided protection against influenza A(H3N2)-related outpatient visits among young persons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
- Marshfield Clinic Research Institute, Wisconsin, USA.
- Department of Pediatrics, Baylor Scott & White Health, USA.
ORCID-Profile: Ashley M Price
Förderung
- NIAID NIH HHS
- CDC
- NIH
Zitieren
APA
Price, A. M., Flannery, B., Talbot, H. K., Grijalva, C. G., Wernli, K. J., Phillips, C. H., Monto, A. S., Martin, E. T., Belongia, E. A., McLean, H. Q., Gaglani, M., Mutnal, M., Geffel, K. M., Nowalk, M. P., Tartof, S. Y., Florea, A., McLean, C., Kim, S. S., Patel, M. M., & Chung, J. R. (2023). Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season. Clinical Infectious Diseases, 76(8), 1358-1363. https://doi.org/10.1093/cid/ciac941
Vancouver
Price AM, Flannery B, Talbot HK, Grijalva CG, Wernli KJ, Phillips CH, et al. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season. Clinical Infectious Diseases. 2023;76(8):1358-1363. doi:10.1093/cid/ciac941
BibTeX
@article{Price2023,
author = {Price, Ashley M and Flannery, Brendan and Talbot, H Keipp and Grijalva, Carlos G and Wernli, Karen J and Phillips, C Hallie and Monto, Arnold S and Martin, Emily T and Belongia, Edward A and McLean, Huong Q and Gaglani, Manjusha and Mutnal, Manohar and Geffel, Krissy Moehling and Nowalk, Mary Patricia and Tartof, Sara Y and Florea, Ana and McLean, Callie and Kim, Sara S and Patel, Manish M and Chung, Jessie R},
title = {Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {8},
pages = {1358--1363},
doi = {10.1093/cid/ciac941}
}
EUVIMED